Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that underscore a strengthening launch trajectory for its Alzheimer's treatment ZUNVEYL, with net product revenue surging 71% sequentially to $6.0 million. The company's performance, detailed in an update from Stonegate Capital Partners, indicates that demand is accelerating even as payer implementation remains limited, suggesting the growth is rooted in real-world adoption rather than inventory stocking.
During the quarter, bottles dispensed increased 37% to 8,294, with June reaching 2,997 bottles—the strongest month since the product's launch. Notably, this growth occurred without any material stocking benefit, and downstream pharmacy benefit manager (PBM) implementation remained steady at approximately 16%. This implies that the revenue increase was driven by genuine prescription demand and improved commercial execution, rather than one-time channel fills.
The breadth of adoption is expanding, with 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers. Additionally, 1,095 long-term care (LTC) facilities generated prescriptions during the quarter, up from 1,095 in the prior quarter, indicating deepening penetration in institutional settings. This dual expansion—more prescribers and higher repeat utilization—provides a solid foundation for continued growth.
Despite the slow pace of PBM implementation, which remains a key catalyst for broader market access, the company is making strides in other areas. Management has lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million-$54 million, reflecting disciplined cost management while maintaining its target of achieving operating profitability by 2027. This balance between investment and efficiency is critical as the company navigates the commercial ramp.
Several potential milestones lie ahead, including the release of CONVERGE data expected in the third quarter of 2026, the ongoing RESOLVE study, and the sublingual program, which is gated by comparative pharmacokinetic results. These developments could provide additional catalysts for the stock and validate the product's clinical profile.
Stonegate Capital Partners, which provides equity research and investor relations services, highlighted that the quality of the quarter was better than the access backdrop suggests. The firm noted that prescriptions, repeat use, and facility adoption all advanced without broader formulary activation, indicating that the core growth is sustainable.
For more details, the full announcement is available at [Stonegate's website](https://www.stonegateinc.com) and additional resources can be accessed via [Reportable](https://www.reportable.com).
